- Home
- BGNE vs CBOE Comparison
BGNE vs CBOE Comparison
Compare BGNE & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGNE
- CBOE
- Stock Information
- Founded
- BGNE 2010
- CBOE 1973
- Country
- BGNE Cayman Islands
- CBOE United States
- Employees
- BGNE N/A
- CBOE N/A
- Industry
- BGNE Biotechnology: Pharmaceutical Preparations
- CBOE Investment Bankers/Brokers/Service
- Sector
- BGNE Health Care
- CBOE Finance
- Exchange
- BGNE Nasdaq
- CBOE Nasdaq
- Market Cap
- BGNE 19.2B
- CBOE 20.7B
- IPO Year
- BGNE 2016
- CBOE 2010
- Fundamental
- Price
- BGNE $175.87
- CBOE $199.87
- Analyst Decision
- BGNE Buy
- CBOE Buy
- Analyst Count
- BGNE 8
- CBOE 12
- Target Price
- BGNE $253.69
- CBOE $208.58
- AVG Volume (30 Days)
- BGNE 476.1K
- CBOE 898.9K
- Earning Date
- BGNE 11-12-2024
- CBOE 02-07-2025
- Dividend Yield
- BGNE N/A
- CBOE 1.26%
- EPS Growth
- BGNE N/A
- CBOE 10.63
- EPS
- BGNE N/A
- CBOE 7.34
- Revenue
- BGNE $3,351,304,621.00
- CBOE $3,955,600,000.00
- Revenue This Year
- BGNE $969.39
- CBOE N/A
- Revenue Next Year
- BGNE $24.79
- CBOE $4.85
- P/E Ratio
- BGNE N/A
- CBOE $27.16
- Revenue Growth
- BGNE 50.22
- CBOE 3.84
- 52 Week Low
- BGNE $126.97
- CBOE $166.13
- 52 Week High
- BGNE $248.16
- CBOE $221.66
- Technical
- Relative Strength Index (RSI)
- BGNE 34.52
- CBOE 41.40
- Support Level
- BGNE $174.50
- CBOE $200.17
- Resistance Level
- BGNE $180.00
- CBOE $202.16
- Average True Range (ATR)
- BGNE 6.73
- CBOE 4.81
- MACD
- BGNE -2.17
- CBOE -1.22
- Stochastic Oscillator
- BGNE 3.24
- CBOE 19.05
About BGNE BeiGene Ltd.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
About CBOE Cboe Global Markets Inc.
Cboe global Markets, Inc is a provider of market infrastructure and tradable products, delivers cutting-edge trading, clearing and investment solutions to market participants around the world. The Company is committed to operating a trusted, inclusive global marketplace, and to providing leading products, technology and data solutions that enable participants to define a sustainable financial future. Cboe provides trading solutions and products in multiple asset classes, including equities, derivatives, FX, and digital assets, across North America, Europe, and Asia Pacific.